RxDoctor Payments Data

Clinton Allen, MD

Family Medicine · Centre, ALNPI 1679598775

Payments from drug & device makers

$6,514in general payments, 2019–2025

Across 416 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$875
  • GSK$750
  • AbbVie$561
  • AstraZeneca$549
  • Otsuka America Pharmaceutical, Inc.$419
  • Lilly USA, LLC$417
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,38998%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,514 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$306,108
Medicare patients
533
Services billed
8,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter366$323,929
EliquisApixaban291$237,886
OzempicSemaglutide129$157,766
MounjaroTirzepatide117$126,647
TrulicityDulaglutide98$122,542
FarxigaDapagliflozin Propanediol156$117,151
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog98$107,461
JardianceEmpagliflozin103$98,867
JanuviaSitagliptin Phosphate102$92,620
XareltoRivaroxaban90$76,596
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$61,239
Tresiba Flextouch U-200Insulin Degludec37$56,700
LinzessLinaclotide50$41,565
EntrestoSacubitril/Valsartan41$36,797
ProliaDenosumab21$35,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$750$377,207451 claims
PfizerEliquis, Nurtec Odt, Premarin$365$266,265328 claims
Lilly USA, LLCMounjaro, Trulicity$417$249,188215 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$549$188,847262 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Synjardy Xr$875$159,780166 claims
Novo NordiskOzempic$131$157,766129 claims
MerckJanuvia, Janumet$206$123,887129 claims
Johnson & JohnsonXarelto$98$76,59690 claims
AbbVieLinzess, Creon$561$73,15971 claims
NovartisEntresto$176$36,79741 claims
AmgenProlia$130$35,77721 claims
Astellas Pharma US IncMyrbetriq$103$20,64335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Centre

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →